|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2004-1-12
|
|
pubmed:abstractText |
Docetaxel (Taxotere) is a taxoid derived from the European yew tree, taxus baccata. In 4 phase-II studies docetaxel has important single agent activity with an overall prostate-specific antigen response rate of 42% in hormone refractory prostate cancer. Other phase-II studies suggest that the addition of estramustine to docetaxel results in a higher response rate but also in an increased toxicity. At present Docetaxel with and without estramustine is being evaluated in phase-III studies that will provide definitive information about its role in hormone refractory prostate cancer.
|
|
pubmed:language |
ger
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0378-584X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2003 S. Karger GmbH, Freiburg
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
26 Suppl 7
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
37-40
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:14716141-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:14716141-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:14716141-Clinical Trials as Topic,
pubmed-meshheading:14716141-Estramustine,
pubmed-meshheading:14716141-Humans,
pubmed-meshheading:14716141-Male,
pubmed-meshheading:14716141-Neoplasm Staging,
pubmed-meshheading:14716141-Prostate-Specific Antigen,
pubmed-meshheading:14716141-Prostatic Neoplasms,
pubmed-meshheading:14716141-Taxoids,
pubmed-meshheading:14716141-Tumor Markers, Biological
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
[Significance of docetaxel in the chemotherapy of hormone-refractory prostate cancer].
|
|
pubmed:affiliation |
Caritas-Krankenhaus, Bad Mergentheim.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
English Abstract,
Review
|
